Literature DB >> 8230495

The management of clinically unconfirmed positive urinary cytology.

D M Schwalb1, H W Herr, W R Fair.   

Abstract

An aggressive evaluation of extravesical sites of disease in patients with clinically unconfirmed positive urinary cytology findings is indicated only in previously untreated asymptomatic or symptomatic patients (group 1) and in those with a complete response to intravesical therapy who are without evidence of disease for 1 year (group 4). Patients who have positive urinary cytology findings immediately after complete transurethral resection of bladder tumors or intravesical therapy will almost always have recurrent bladder transitional cell carcinoma and do not require aggressive extravesical evaluation initially. Transurethral resection prostate biopsy between the 5 and 7 o'clock positions along the entire length of the prostatic urethra is the technique of choice for detecting transitional cell carcinoma of the prostate, since other less invasive techniques frequently underestimate the extent of disease. In the absence of radiographic disease, bilateral ureteral lavage cytology is the technique of choice to identify the upper tract as the source of a positive urinary cytology result. Rigid and flexible ureteropyeloscopy should be performed only in the presence of radiographic or cytological evidence of upper tract transitional cell carcinoma, or in patients with a history of upper tract disease who have suspected relapse on the basis of a positive urinary cytology result.

Entities:  

Mesh:

Year:  1993        PMID: 8230495     DOI: 10.1016/s0022-5347(17)35886-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

Review 1.  [Urine cytology - update 2013. A systematic review of recent literature].

Authors:  M Böhm; F vom Dorp; M Schostak; O W Hakenberg
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

2.  The efficacy of urinary cytology in the detection of recurrent bladder tumours.

Authors:  S Baltaci; O Süzer; G Ozer; Y Bedük; O Göğüş
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

Review 3.  Bladder tumor markers: need, nature and application. 1. Nucleus-based markers.

Authors:  M M Kirollos; S McDermott; R A Bradbrook
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1998

4.  A singular case of intravesical bleeding angiomyolipoma in a bladder diverticulum.

Authors:  Michael E Chua; Maria Anna Vanessa A Geron
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

Review 5.  [Urinary cytology in cases of bladder cancer: a critical evaluation].

Authors:  P Rathert
Journal:  Urologe A       Date:  2003-03-26       Impact factor: 0.639

6.  Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder.

Authors:  Matteo Santoni; Francesco Catanzariti; Daniele Minardi; Luciano Burattini; Massimo Nabissi; Giovanni Muzzonigro; Stefano Cascinu; Giorgio Santoni
Journal:  Adv Urol       Date:  2012-07-02

7.  Urine BLCA-4 exerts potential role in detecting patients with bladder cancers: a pooled analysis of individual studies.

Authors:  Qiliang Cai; Yudong Wu; Zhanjun Guo; Rui Gong; Yang Tang; Kuo Yang; Xiaodong Li; Xuemei Guo; Yuanjie Niu; Yan Zhao
Journal:  Oncotarget       Date:  2015-11-10

8.  Diagnostic accuracy of the UBC® Rapid Test for bladder cancer: A meta-analysis.

Authors:  Pei Lu; Jianchun Cui; Keliang Chen; Qiang Lu; Jiexiu Zhang; Jun Tao; Zhijian Han; Wei Zhang; Rijin Song; Min Gu
Journal:  Oncol Lett       Date:  2018-07-05       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.